Peptides & Complex Generics Symposium 2026 Returns to Mumbai
**Panel Discussion | The Rapid Rise of GLP-1 Drugs, Weight Loss, Wellness & Beyond** As part of the **inaugural edition of Peptides & Complex Generics (PCG)**, this insightful panel brought together leading voices from across the pharmaceutical and healthcare ecosystem to discuss the rapidly evolving landscape of GLP-1 drugs and their impact on weight loss, wellness and beyond. Featuring, from left to right: **Mr. Vikas Dandekar**, Editor (Pharma and Healthcare), The Economic Times **Mr. Vikrant Shrotriya**, Corporate Vice President and Managing Director, Novo Nordisk **Mr. Winselow Tucker**, President, Eli Lilly & Co. (India) Pvt. Ltd. **Mr. Siddharth Mittal**, MD & CEO, Syngene International; Ex-CEO & MD, Biocon Ltd. **Dr. Subramanian Narayanaswamy**, Head of Delivery, Parenteral Injectables – IPDO, Dr. Reddy’s Laboratories **Mr. Jatin Vimal**, Director, Levim Lifetech Pvt. Ltd. A powerful discussion reflecting the growing significance of GLP-1 therapies and the opportunities and challenges shaping the future of this rapidly advancing space. #PCG2026 #Peptides #GLP1 #Pharma #Healthcare
20260904181315.webp&w=1920&q=75&dpl=dpl_CE3VACNCZ5AoAf3CQ76nP9jikDry)
MUMBAI, INDIA — Following the success of its inaugural edition, Mumbai Biocluster, a
Section-8 not-for-profit institution under the Institute of Chemical Technology (ICT), Mumbai,
has announced the second edition of the Peptides & Complex Generics Symposium (PCG
2026). The symposium will take place on 28–29 September 2026 at Aurika by Lemon Tree
Hotels, Mumbai.
As the pharmaceutical industry rapidly expands beyond traditional generics into complex
therapeutics such as peptides, oligonucleotides, and long-acting injectables, there is an
increasing need for expertise across manufacturing, analytical characterization, regulatory
science, and commercialization. PCG 2026 will bring together global experts, industry leaders,
regulators, policy makers and researchers to address these challenges and accelerate
innovation in complex therapeutics.
A signature addition to this year's programme is the Billion Dose Challenge—an industry-led
initiative exploring how India can manufacture and deliver complex therapeutics at population-
scale while maintaining quality, affordability, and regulatory excellence. By placing this
challenge at the centre of PCG 2026, Mumbai Biocluster aims to foster actionable strategies that
strengthen India's position as both an innovation hub and a global supplier of advanced
medicines.
"India has already proven, it can make medicines affordable — the real test now is whether we can
make complex therapeutics like peptides available at population scale, without compromising on
quality or speed. The Billion Dose Challenge is our way of putting that question at the centre of the
conversation, not at the margins. Through PCG 2026, we want to bring together the people who
build, regulate, and finance these medicines, so that India moves from being a fast follower to a
genuine architect of how the world manufactures complex therapeutics."
— Dr. Ratnesh Jain, Founder & Director, Mumbai Biocluster
Key Highlights
• Plenary Discussions on the Billion Dose Challenge and Beyond China +1, building
resilient global supply chains for complex therapeutics.
• Global Speakers from leading pharmaceutical companies, technology providers, and
research organizations like CEM Scientific Private Limited,Consulate General of
Switzerland and OneSource Specialty Pharma Limited sharing insights on peptide
manufacturing, GLP-1 therapies, oligonucleotides, and regulatory science.
• Technical Workshops covering peptide purification and next-generation
oligonucleotide facility design with practical, industry-focused training.
• Innovation Opportunities through abstract presentations, awards, travel grants, and
recognition for young researchers.
• Molecule-to-Market Expo showcasing cutting-edge technologies from leading global
and Indian life sciences company like Sartorius Stedim India Private Limited, Cytiva,
Agilent Technologies India Private Limited, Invitron Advanced Analytics Private
Limited, Hitachi High-Tech India Private Limited and more.
• Networking Platform connecting academia, industry, policymakers, startups, investors,
and technology providers.
PCG 2026 offers participants an opportunity to gain scientific insights, discover emerging
technologies, build strategic partnerships, and contribute to shaping the future of peptide and
complex therapeutics.
PCG 2026 accelerates your journey from discovery to commercial impact.
Be a part of the dialogue that matters. Be a part of #PCG2026.
Registrations & Partnerships:
Registrations, poster submissions, and sponsorship opportunities are open. Visit:
For partnership and exhibition enquiries, reach out to:
Ms. Simran Siddiqui, Marketing Associate. [email protected] |
+91 93727 10286
For registration queries, reach out to:
Tejal Khanna, Sales Executive. [email protected] | +91 93722 10650
Neha Gupta, Sales Executive. [email protected] | +91 87791 97872
Chaitya Shah, Sales Associate. [email protected] | +91 93213 84357Peptides & Complex Generics Symposium 2026, PCG 2026, peptide therapeutics, complex generics,
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Discussion